CHARNWOOD MOLECULAR LAUNCHES NEW WEBSITE
Added: (Tue May 10 2022)
Pressbox (Press Release) -
Charnwood Molecular, a leading UK-based pre-clinical discovery CRO serving the global pharmaceutical and biotechnology market, has launched a new website outlining in detail the company’s integrated drug discovery capabilities.
The new site clearly sets out the company’s integrated drug discovery services along with its capabilities in bioscience, medicinal chemistry, computational chemistry and early scale-up.
The new website has been created after consultation with Charnwood Molecular’s clients and team, to apply improvements to the site.
The new site also includes dedicated sections for drug discovery, therapeutic areas, target classes and resources.
Amongst other enhancements, there is improved navigation making it easier to see how Charnwood Molecular can work with clients as an integrated drug discovery service provider.
The new website is the latest in a line of key developments for Charnwood Molecular, with the company having very recently officially opened its flagship new facilities at Charnwood Campus, Loughborough. These premises house the company’s key scientific teams working on areas from bioscience through to medicinal chemistry.
Charnwood Molecular is ideally placed now to offer an ever-expanding number of services.
EDITORS’ NOTES
ABOUT CHARNWOOD MOLECULAR
In 2019 Charnwood Molecular was acquired by leading Private Equity group, Synova. The deal provided the company with additional investment to support its continued development and growth. Synova continues to support Charnwood Molecular to deliver an ambitious growth plan, built upon increasing investment in the business’s core capabilities as a trusted partner in innovative chemistry, alongside expanding its service offering into complementary scientific disciplines.
In 2022 Charnwood Molecular relocated its BioCity and Loughborough operations to a single-site, state-of-the-art laboratory complex based in world-class facilities at Charnwood Campus, Loughborough. The campus was recently designated a “Life Sciences Opportunity Zone”, providing an environment to inspire discovery, encourage collaboration and accelerate business growth within the Med-Tech and Biopharma industries.
Charnwood Molecular's portfolio of services is wide and currently includes:
• Fully integrated drug discovery
• Customised bioassay development
• Medicinal Chemistry (design, synthesis and multi-parameter optimisation of drug molecules for discovery projects; computational chemistry and emerging synthetic technologies)
• Custom Synthesis preparation of key chemical intermediates on up to 20-litre scale
• Chemical Development and Process Research Services including route design, development and optimization